Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
Open Access
- 12 July 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 29713
Abstract
Osteoprotegerin (OPG), receptor activator of nuclear factor-ΚB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been involved in rheumatoid arthritis (RA) pathophysiology. In this study, we assessed messenger RNA (mRNA) expression of these molecules by qPCR in peripheral blood from 26 patients with RA (12 of them with ischemic heart disease –IHD) and 10 healthy controls. Correlation coefficients between OPG, RANKL and TRAIL expression levels in RA patients and their clinical and demographic characteristics were also evaluated. Whereas OPG and OPG/TRAIL ratio expression were significantly increased in RA patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL and TRAIL expression. Interestingly, TRAIL expression was significantly higher in RA patients with IHD compared to those without IHD (fold change = 1.46, p = 0.033). Moreover, biologic disease-modifying antirheumatic drugs (DMARDs) significantly decreased RANKL expression in RA patients (p = 0.016). Our study supports an important role of OPG and TRAIL in RA. Furthermore, it highlights an effect of biologic DMARDs in the modulation of RANKL.Keywords
This publication has 23 references indexed in Scilit:
- The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritisCytokine, 2013
- TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what’s new?Clinical and Experimental Medicine, 2012
- Genetic Markers of Cardiovascular Disease in Rheumatoid ArthritisMediators of Inflammation, 2012
- The role of RANK ligand/osteoprotegerin in rheumatoid arthritisTherapeutic Advances in Musculoskeletal Disease, 2012
- An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarctionAtherosclerosis, 2010
- Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and MorbidityJACC, 2010
- Is there any role for tumour necrosis factor related apoptosis inducing ligand–osteoprotegerin (TRAIL–OPG) interaction in rheumatoid arthritis?Annals of the Rheumatic Diseases, 2008
- Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophilsArthritis Research & Therapy, 2007
- Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritisRheumatology, 2006
- High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatmentArthritis & Rheumatism, 2002